These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30320629)

  • 41. A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis.
    Zhao Y; Schaafsma E; Gorlov IP; Hernando E; Thomas NE; Shen R; Turk MJ; Berwick M; Amos CI; Cheng C
    Mol Cancer Res; 2019 Jan; 17(1):109-119. PubMed ID: 30171176
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression.
    Mueller DW; Bosserhoff AK
    Int J Cancer; 2011 Sep; 129(5):1064-74. PubMed ID: 21077158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
    Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
    Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
    [No Abstract]   [Full Text] [Related]  

  • 44. Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer.
    Durante G; Broseghini E; Comito F; Naddeo M; Milani M; Salamon I; Campione E; Dika E; Ferracin M
    Expert Rev Mol Diagn; 2022 Mar; 22(3):305-318. PubMed ID: 35235479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Molecular classification and markers of malignant melanoma].
    Tímár J; Hársing J; Somlai B
    Magy Onkol; 2013 Jun; 57(2):73-8. PubMed ID: 23795351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
    Jayawardana K; Schramm SJ; Tembe V; Mueller S; Thompson JF; Scolyer RA; Mann GJ; Yang J
    J Invest Dermatol; 2016 Jan; 136(1):245-254. PubMed ID: 26763444
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNAs role as potential biomarkers and key regulators in melanoma.
    Varamo C; Occelli M; Vivenza D; Merlano M; Lo Nigro C
    Genes Chromosomes Cancer; 2017 Jan; 56(1):3-10. PubMed ID: 27561079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantification of microRNA-21 and microRNA-125b in melanoma tissue.
    Wandler A; Riber-Hansen R; Hager H; Hamilton-Dutoit SJ; Schmidt H; Nielsen BS; Stougaard M; Steiniche T
    Melanoma Res; 2017 Oct; 27(5):417-428. PubMed ID: 28614272
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diversity of circulating tumor cells in peripheral blood: Detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis.
    Kiniwa Y; Nakamura K; Mikoshiba A; Akiyama Y; Morimoto A; Okuyama R
    J Dermatol Sci; 2018 May; 90(2):211-213. PubMed ID: 29426605
    [No Abstract]   [Full Text] [Related]  

  • 50. Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma.
    Svedman FC; Lohcharoenkal W; Bottai M; Brage SE; Sonkoly E; Hansson J; Pivarcsi A; Eriksson H
    PLoS One; 2018; 13(11):e0206942. PubMed ID: 30399176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Update on melanoma epigenetics.
    de Unamuno B; Palanca S; Botella R
    Curr Opin Oncol; 2015 Sep; 27(5):420-6. PubMed ID: 26197354
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine.
    Mumford SL; Towler BP; Pashler AL; Gilleard O; Martin Y; Newbury SF
    Biomolecules; 2018 Apr; 8(2):. PubMed ID: 29701682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.
    Caramuta S; Egyházi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui WO
    J Invest Dermatol; 2010 Aug; 130(8):2062-70. PubMed ID: 20357817
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monitoring Melanoma Using Circulating Free DNA.
    Diefenbach RJ; Lee JH; Rizos H
    Am J Clin Dermatol; 2019 Feb; 20(1):1-12. PubMed ID: 30374893
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MicroRNA-153-3p suppress cell proliferation and invasion by targeting SNAI1 in melanoma.
    Zeng HF; Yan S; Wu SF
    Biochem Biophys Res Commun; 2017 May; 487(1):140-145. PubMed ID: 28400282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Melanoma: Where we are and where we go.
    Mohammadpour A; Derakhshan M; Darabi H; Hedayat P; Momeni M
    J Cell Physiol; 2019 Apr; 234(4):3307-3320. PubMed ID: 30362507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current staging and prognostic factors in melanoma.
    Bartlett EK; Karakousis GC
    Surg Oncol Clin N Am; 2015 Apr; 24(2):215-27. PubMed ID: 25769707
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiproliferative and Pro-Apoptotic Effects of MiR-4286 Inhibition in Melanoma Cells.
    Komina A; Palkina N; Aksenenko M; Tsyrenzhapova S; Ruksha T
    PLoS One; 2016; 11(12):e0168229. PubMed ID: 28005927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis.
    Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T
    Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum angiogenin levels predict treatment response in patients with stage IV melanoma.
    Vihinen P; Kallioinen M; Vuoristo MS; Ivaska J; Syrjänen KJ; Hahka-Kemppinen M; Kellokumpu-Lehtinen PL; Pyrhönen SO
    Clin Exp Metastasis; 2007; 24(7):567-74. PubMed ID: 17762972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.